D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Identifieur interne : 000A22 ( Main/Exploration ); précédent : 000A21; suivant : 000A23D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Auteurs : Carole Hyacinthe [France] ; Quentin Barraud [France] ; François Tison [France] ; Erwan Bezard [République populaire de Chine] ; Imad Ghorayeb [France]Source :
- Neurobiology of disease [ 1095-953X ] ; 2014.
English descriptors
- KwdEn :
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (therapeutic use), Analysis of Variance, Animals, Disease Models, Animal, Dopamine Agonists (therapeutic use), Dose-Response Relationship, Drug, Electrocardiography, Electroencephalography, Electromyography, Female, Levodopa (therapeutic use), Macaca fascicularis, Macaca mulatta, Parkinsonian Disorders (complications), Parkinsonian Disorders (drug therapy), Quinpirole (therapeutic use), Sleep (drug effects), Sleep Disorders, Circadian Rhythm (drug therapy), Sleep Disorders, Circadian Rhythm (etiology), Telemetry, Time Factors, Wakefulness (drug effects).
- MESH :
- chemical , therapeutic use : 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, Dopamine Agonists, Levodopa, Quinpirole.
- complications : Parkinsonian Disorders.
- drug effects : Sleep, Wakefulness.
- drug therapy : Parkinsonian Disorders, Sleep Disorders, Circadian Rhythm.
- etiology : Sleep Disorders, Circadian Rhythm.
- Analysis of Variance, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Electrocardiography, Electroencephalography, Electromyography, Female, Macaca fascicularis, Macaca mulatta, Telemetry, Time Factors.
Abstract
Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy. We report here that dopamine agonists act differentially on sleep architecture in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque monkey. Continuous sleep and wake electroencephalographic monitoring revealed no effect of the selective dopamine D2 receptor agonist quinpirole on EDS, whereas the selective dopamine D1 receptor agonist SKF38393 efficiently alleviated EDS and restored REM sleep to baseline values. The present results question the relevance of abandoning D1 receptor agonist treatment in PD as it might actually improve sleep-related disorders.
Url:
DOI: 10.1016/j.nbd.2013.10.029
PubMed: 24211719
Affiliations:
- France, République populaire de Chine
- Aquitaine, Nouvelle-Aquitaine
- Bordeaux, Pékin
- Université de Bordeaux
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000609
- to stream PubMed, to step Curation: 000587
- to stream PubMed, to step Checkpoint: 000587
- to stream Ncbi, to step Merge: 001256
- to stream Ncbi, to step Curation: 001256
- to stream Ncbi, to step Checkpoint: 001256
- to stream Hal, to step Corpus: 000249
- to stream Hal, to step Curation: 000249
- to stream Hal, to step Checkpoint: 000285
- to stream Main, to step Merge: 000A33
- to stream Main, to step Curation: 000A22
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.</title><author><name sortKey="Hyacinthe, Carole" sort="Hyacinthe, Carole" uniqKey="Hyacinthe C" first="Carole" last="Hyacinthe">Carole Hyacinthe</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: carole.hyacinthe@u-bordeaux2.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Barraud, Quentin" sort="Barraud, Quentin" uniqKey="Barraud Q" first="Quentin" last="Barraud">Quentin Barraud</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: quentin.barraud@epfl.ch.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac, France. Electronic address: francois.tison@chu-bordeaux.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac</wicri:regionArea><wicri:noRegion>Pessac</wicri:noRegion><orgName type="university">Université de Bordeaux</orgName><placeName><settlement type="city">Bordeaux</settlement><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region></placeName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China. Electronic address: erwan.bezard@u-bordeaux2.fr.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux Pellegrin, Bordeaux, France. Electronic address: imad.ghorayeb@u-bordeaux2.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux Pellegrin, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24211719</idno><idno type="pmid">24211719</idno><idno type="doi">10.1016/j.nbd.2013.10.029</idno><idno type="wicri:Area/PubMed/Corpus">000609</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000609</idno><idno type="wicri:Area/PubMed/Curation">000587</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000587</idno><idno type="wicri:Area/PubMed/Checkpoint">000587</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000587</idno><idno type="wicri:Area/Ncbi/Merge">001256</idno><idno type="wicri:Area/Ncbi/Curation">001256</idno><idno type="wicri:Area/Ncbi/Checkpoint">001256</idno><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01048645</idno><idno type="url">https://hal.archives-ouvertes.fr/hal-01048645</idno><idno type="wicri:Area/Hal/Corpus">000249</idno><idno type="wicri:Area/Hal/Curation">000249</idno><idno type="wicri:Area/Hal/Checkpoint">000285</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000285</idno><idno type="wicri:doubleKey">0969-9961:2014:Hyacinthe C:d:receptor:agonist</idno><idno type="wicri:Area/Main/Merge">000A33</idno><idno type="wicri:Area/Main/Curation">000A22</idno><idno type="wicri:Area/Main/Exploration">000A22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.</title><author><name sortKey="Hyacinthe, Carole" sort="Hyacinthe, Carole" uniqKey="Hyacinthe C" first="Carole" last="Hyacinthe">Carole Hyacinthe</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: carole.hyacinthe@u-bordeaux2.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Barraud, Quentin" sort="Barraud, Quentin" uniqKey="Barraud Q" first="Quentin" last="Barraud">Quentin Barraud</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: quentin.barraud@epfl.ch.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac, France. Electronic address: francois.tison@chu-bordeaux.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac</wicri:regionArea><wicri:noRegion>Pessac</wicri:noRegion><orgName type="university">Université de Bordeaux</orgName><placeName><settlement type="city">Bordeaux</settlement><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region></placeName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China. Electronic address: erwan.bezard@u-bordeaux2.fr.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux Pellegrin, Bordeaux, France. Electronic address: imad.ghorayeb@u-bordeaux2.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux Pellegrin, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author></analytic><series><title level="j">Neurobiology of disease</title><idno type="eISSN">1095-953X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (therapeutic use)</term><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine Agonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Electroencephalography</term><term>Electromyography</term><term>Female</term><term>Levodopa (therapeutic use)</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Parkinsonian Disorders (complications)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Quinpirole (therapeutic use)</term><term>Sleep (drug effects)</term><term>Sleep Disorders, Circadian Rhythm (drug therapy)</term><term>Sleep Disorders, Circadian Rhythm (etiology)</term><term>Telemetry</term><term>Time Factors</term><term>Wakefulness (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Quinpirole</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Sleep</term><term>Wakefulness</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term><term>Sleep Disorders, Circadian Rhythm</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sleep Disorders, Circadian Rhythm</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Electroencephalography</term><term>Electromyography</term><term>Female</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Telemetry</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy. We report here that dopamine agonists act differentially on sleep architecture in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque monkey. Continuous sleep and wake electroencephalographic monitoring revealed no effect of the selective dopamine D2 receptor agonist quinpirole on EDS, whereas the selective dopamine D1 receptor agonist SKF38393 efficiently alleviated EDS and restored REM sleep to baseline values. The present results question the relevance of abandoning D1 receptor agonist treatment in PD as it might actually improve sleep-related disorders.</div></front></TEI><affiliations><list><country><li>France</li><li>République populaire de Chine</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li><li>Pékin</li></settlement><orgName><li>Université de Bordeaux</li></orgName></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Hyacinthe, Carole" sort="Hyacinthe, Carole" uniqKey="Hyacinthe C" first="Carole" last="Hyacinthe">Carole Hyacinthe</name></region><name sortKey="Barraud, Quentin" sort="Barraud, Quentin" uniqKey="Barraud Q" first="Quentin" last="Barraud">Quentin Barraud</name><name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24211719
|texte= D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24211719" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |